·OÀÙ°©Å讽ÃØ ¬O§U¤H¡HÁÙ¬O®`¤H¡H ¡]http://37tcm.wordpress.com/2009/04/21/%E6%85%88%E6%BF%9F%E9%AA%A8%E9%AB%93%E6%8D%90%E8%B4%88-%E6%98%AF%E5%8A%A9%E4%BA%BA%EF%BC%9F%E9%82%84%E6%98%AF%E5%AE%B3%E4%BA%BA%EF%BC%9F/
¡^
Posted
on
«á¾Ç¤@ª½»{¬°¡A°µ¦n¨Æ¤£¦p°µ¹ïªº¨Æ¡A¦n¨Æ¦³®É¤£¤@©w¬O¹ïªº¨Æ¡C®½°©Åè¬O§U¤H¡H
®`¤H¡H¤£§«¬Ý¬Ý¥H¤U¤å³¹¡C
¼gµ¹·OÀÙ®v©jªº¤@«Ê«H
¿Ë·Rªº·OÀÙ®v©j¡A¤]³\©p¤£»{ÃѧڡA¦ý¬O§Ú̦³¤@±¤§½t¡A«Ü©êºp¼g³o¤@«Ê«Hµ¹±z¡A¦³¨Ç¨Æ±¡§Ú·QÅý©pª¾¹D¡C
¨º¤Ñ¡Aª¿¨¦ªº·OÀÙ¤¤¤å¾Ç®Õ¿ì·s¬K¶é¹C·|¡A¨C¤@Ó¯Z¯Å³£¦³¦Û¤v¯Z¤WªºÅu¦ì¡C¥H©¹ªº¶é¹C·|¡A¦Y¦Y³Ü³ÜªºÅu¦ì³Ì¦h¡A¤pªB¤Í¤]«Ü³ßÅw¡A¦ý¬O¨C¦¸¦Y§¹¡A©U§£±í¸Ìº¡º¡ªº§K¬~À\¨ã¡A¦n¤£®ö¶O¡C¤µ¦~¥D¿ì³æ¦ì¨M©w¡A¤£¯à¦A¦³½æ¦YªºÅu¦ì¡A©Ò¥H¤µ¦~³£¬Oª±¤@¨Ç¤p¹CÀ¸ªºÅu¦ì¡A²{³õ¤]«D±`¼ö¾x¡C§Ú¤@¤â²oµÛ¨à¤l¡A¤@¤â²oµÛ¤k¨à¡A¨«¶i¤F¼ö¾x¯M¯Mªº·|³õ¡C
¦b·|³õªº¤@¨¤¡A§Ú¬Ý¨ì¤F©p̪ºÅu¦ì¡A¤j¤jªº¦rÅý¤H«ÜÃø¤£¬Ý¨ì¡A¡u·OÀÙ¥\¼w·|°©Å讽ÃØ¡v¡C§Ú¤ßÀY¤@»þ¡A¨º¹Ð«Ê¤w¤[ªº©¹¨Æ¥ß¨è¯B¤W¤ßÀY¡A¤U·NÃѪº¡A§Ú±aµÛ¨à¤l¦V¥t¤@Ã䨫¥h¡C©p¬Ý¨ì§Ú¤F¡A§Ú¤ß¸Ìª¾¹D¡A©p¦b¦V§Ú¨«¹L¨Ó¡C©pº¡Áy¯º®e¡A§Ú§CµÛÀY·Q°kÁסCÁÙ¬O³Q©pÄd¦í¤F¡C
©p¢¤£¤Î«Ýªº§i¶D§Ú¤°»ò¥s¥Õ¦å¯f¡A¦h»ò¥i©Èªº¥Õ¦å¯f¡A¤j¤H¡B¤p«Ä¡BÀ¦¨à¡B¦Ñ¤H¡B¦~»´¤H³£·|±o¨ì¡C©p¶ëµ¹§Úªº¤p¥U¤l¤W¡A¦LµÛ¤@±i±i¯íµMªºÁy¤Õ¡C©p§i¶D§Ú¡A¥LÌ °ß¤@ªº§Æ±æ¡A´N¬O°©Åè²¾´Ó¡A°ß¦³°©Åè²¾´Ó¤~¯à±Ï¥L̪º©R¡C¦b©pªº²´¸Ì¡A§Ú¬Ý¨ì¤F¤@Ó·OÀÙ¤Hªº¯u¸Û¡A©p°J¤ßªº§Æ±æ§Ú¯à¥[¤J°©Å讽Ãتº¸ê®Æ®w¡C©p§i¶D§Ú¡A³s¦å³£¤£¥Î©â¡A¥un¥Î¤@Ó´Öªá´Î¡A¦b¤fµÄ¤º°¼¨í¤@¤U´N¦n¡A¤@ÂI³£¤£·|µh¡C§Ú¹ï·OÀÙ¤H¡AÁ`¬O¦³µÛ±R°ªªº·q·N¡A¨ØªA¦o̪º±¡¾Þ¡A¦b¦h¦¸ªº±ÏÃø¬¡°Ê¤¤¡A¬ÝµÛ·OÀÙ¤H¦b ¶¤¥î¤¤¦£¸L¡A§ÚÁ`¬O¤Q¤À·P°Ê¡C
¥i¬O¡A³o¦¸§Ú¨S¦³·P°Ê¡C
®v©j¡A©p¥iª¾¹D¡A§Ú¬Ý¹Lªº¥Õ¦å¯f¤H¡A¤ñ°_©p¨Ó¡A¤£ª¾¦h¤F¦h¤Ö¡C¥Õ¦å¯f¤H¹ï©p¨ÓÁ¿¡A¥i¯à¥u¬OÓ¦Wµü¡A¦ý¬O¡A¹ï§Ú¨Ó»¡¡A«o¬O¤@³õ²`¨èªº¦^¾Ð¡C§Ú¤£¤î¬Ý¹L¡AÁÙ³¤F«Ü¦h¤H¡A¨«¹L¤F¥L̥ͩR¤¤ªº³Ì«á¤@¬q¸ô¡C©p±À¼sªº°©Åè²¾´Ó¡A§Ú¤]´¿¸g¬Û«H¡A¦ý¬O¡A¦b¬Ý¹L¤@ÓÓ¥¢±Ñªº¨Ò¤l«á¡A§Ú¨S¦³¿ìªk¦A¬Û«H¡C
©pª¾¹D°©Åè²¾´Ó¬O¦p¦ó¶i¦æªº¶Ü¡H¦b¤d¨¯¸UW§¹¦¨°©Åè°t¹ï¤§«á¡A§â¯f¤Hªº°©Åè©â¥X¨Ó¡A§â®½Ãت̪º©ñ¶i¥h¡A³o¼Ë´N§¹¦¨¤F¶Ü¡H¿ù¤F¡A¬°¤F©È¯f¤H¿ò¯d¦b¨Å骺°©Å褤¤´µM¦³¡uÃa¡vªº¥Õ¦å²y¡A¦b°©Åè²¾´Ó¤§«e¡A¯f¤Hn§@¥þ¨¤j¾¯¶qªº¤ÆÀø¡A¥[¤W©ñÀø¡A¤]´N¬On°í¾À²M³¥¡A¤£¯d¤U¥ô¦ó¤@ÓÃa¥÷¤l¡C³oÓ¹Lµ{¤¤¡A¦nªºÃaªº¦å²y³q³q±þ¥ú¡AµM«á¦A§â®½Ãتº°©Åè©ñ¶i¨Ó¡C¦¹®É¡A¯f¤H¤@©w«D±`µê®z¡A¥²¶·¦b¹jÂ÷¯f©Ð¦í¤W«Üªøªº¤@¬q¤é¤l¡Aµ¥«Ý¦å²yªº««Ø¡C³oÓ¹Lµ{¤¤¡A¥ô¦ó¤@Ó¦W¤£¨£¸g¶Çªº¤p²Óµß¡A ³£¯àn¤F¯f¤Hªº©R¡A¦]¬°¯f¤Hµ¥©ó¥þ¤£³]¨¾¡A¨¤W¨S¦³¤@ÂI¨¾¿mªº¯à¤O¡C§Ú»{ÃѪº¥Õ¦å¯f¤H¡A³£¬O¦b³oÓ¶¥¬q·P¬V«á¡AÂ÷¶}¤H¥@¡C
©È©p¤£¬Û«H¡A§Ú¦bºû°ò¦Ê¬ì§ä¤F¸ê®Æ¡A¨Ó¦õÃÒ§Úªº»¡ªk¡C
http://en.wikipedia.org/wiki/Bone_marrow_transplantation
Autologous HSCT requires the
extraction (Apheresis) of haematopoietic stem cells (HSC) from the patient and
storage of the harvested cells in a freezer. The patient is then treated with high-dose chemotherapy with or without radiotherapy
with the intention of eradicating the patient¡¦s malignant cell population at the cost of partial or complete bone marrow
ablation (destruction of patient¡¦s bone marrow function to grow new blood cells). The patient¡¦s own stored stem cells are then returned to his/her
body, where they replace destroyed tissue and resume the patient¡¦s normal blood cell production. Autologous
transplants have the advantage of lower risk of infection during the
immune-compromised portion of the treatment since the recovery of immune
function is rapid. Also, the incidence of patients experiencing rejection (graft-versus-host
disease) is very rare due to the donor and recipient being the same individual.
These advantages have established autologous HSCT as one of the standard
second-line treatments for such diseases as lymphoma.[9]
However, for others such as Acute Myeloid Leukemia, the reduced mortality of
the autogenous relative to allogeneic HCST may be outweighed by an increased
likelihood of cancer relapse and related mortality, and therefore the
allogeneic treatment may be preferred for those conditions.[10]
¤]³\©p·|»¡¡A¤£ºÞªvÀøªº¹Lµ{¦p¦ó§xÃø¡A¦³®ÄªG´Nȱo¥h§@¡A§Ú¦P·N¡A¨º»ò¦¨¥\ªº¼Æ¾Ú¦bþ¸Ì©O¡H§Ú§ä¤F¤S§ä¡A¦b·OÀÙªººô¯¸¤W³£§ä¤£¨ì©ú½Tªº¸ê®Æ¡A©pÁ`¸Ó§i¶D§Ú¨ì©³¦³´X¨Ò¦¨¥\ªº®×¨Ò§a¡H§Ú²×©ó§ä¨ì¤F³oÓ¡G
How to Understand
ùر©p¥i¥H¬Ý¨ì¥þ¬ü¦UÓÂåÀø¾÷ºcÃö©ó°©Åè²¾´Óªº²Îp¸ê®Æ¡C³oùظê®Æ«Ü¦h¡A§ÚÌ´N¨Ó¬Ý¬ÝÆW°Ï³ÌµÛ¦Wªº¥v¤¦ºÖ¤j¾Çªºªþ³]Âå°|§a¡I
Blood and Marrow Transplant Program
Center-Specific Analysis
This analysis is based on
transplants performed from Jan. 1, 2002 through Dec
31, 2006, using unrelated NMDP donors. It only includes patients who
were confirmed to be either alive or deceased within one year of transplant.
1.
This center reported survival
status data for 184 patients.
2.
The overall disease condition
of patients treated at this center was in the low category (1 on a scale
of 1 to 5).
3.
The actual one-year survival of these patients was 62.4%.
4.
The predicted one-year survival
was 61.0% (with 95% statistical confidence
that the predicted survival was between 54.4% and 68.1%).
5.
This center¡¦s actual results are similar to the predicted
range for this center. National one-year estimated actual survival was 54.0% in
the 8,847 patients transplanted in the
³oÓ¸ê®Æ«Ü¦³½ì¡A±q2002¨ì2006Á`¦@¤¦~¡A§@¤F184¦ì¯f¤H¡C³oÓ¤ÀªR³£¬O¥H¦¨¥\ªº¤è¦V¨Ó³ø¾É¡AÅý§Ú¥Î¥t¥~¤@Ó¤è¦V¨Ó¸ÑÄÀ¡G
¡P
²Ä¤T±ø©M²Ä¥|±øªº·N«ä¬O¡A¦pªG¯f¤H§@°©Åè²¾´Ó¡A¤@¦~¤§¤º¬ù¦³¤@¥bªº¾÷·|¡A¯f¤H·|¥á¤F©Ê©R¡C
¡P
²Ä¤T±ø·t¥Ü»¡¡A²Ä¤@¦~¥H«á¡A¯f¤H¥á±¼©Ê©Rªº¾÷·|¡A±N·|¤j38%¡]100% ¡V 62.4%)¡C ¬Æ¦Ü§Ú¥i¥H±À´ú¡A¨â¦~ªº¦s¬¡²v¡A±N»·¤p©ó62.4%¡C±z»¡¬O¶Ü¡H¦pªG¨â¦~ªº¦s¬¡²v¤ñ³oÓ¤j¡A¨º¬°¤°»ò³o½g¤ÀªR±qÀY¨ì§À³£¥u»¡¤@¦~¤ºªº¦s¬¡²v©O¡H
¡P
°²³]¨C¦~³£¦³50%ªº¾÷²v¯f¤H·|¥á¤F©Ê©R¡A¨º»ò¤T¦~ªº¦s¬¡²v±N¬O¡G12.5% (50% * 50% * 50%)
³o¼Ë¤l¨Óºâ¡A´N«Ü±µªñ§Ú¦b¥x¤jÂå°|ªº¸gÅç¤F¡C½Ð°Ýþ¸Ì¥i¥H¬Ý¨ì·OÀÙªº¼Æ¾Ú©O¡H¦pªG¦¨¥\ªº¾÷²v¬O¤@¥b¡A¨º¤£´«°©Åè¡B¤£§@¤ÆÀø¡A¯à¤£¯à¹F¨ì¤@¦~¤º62.4%ªº¦s¬¡²v©O¡H
©Ò¥H¡A¿Ë·Rªº·OÀÙ®v©j¡A§Ú¯uªº¤£·Q®½°©Åè¡C
by ¬W¤l
¤å³¹¨Ó·½¡G ¼gµ¹·OÀÙ®v©jªº¤@«Ê«H
(§@ªÌ¬°°õ·~¤¤Âå®v)¡C
ì¤å¤¤ªº¬õ¦â¦r§ï¬°¾ï¦â¦r¡A¦Ó¬õ¦â¦r¬°«á¾Ç©Ò¼Ð°O¡C